

Cumulative Table of Contents Psychopharmacology Bulletin

Vol. 30, No. 1—1994

NCDEU 1993 Annual Meeting— Papers and Abstracts

Design and Methodology Issues for Clinical Treatment Trials in Children and Adolescents

- 3** Child and Adolescent Psychopharmacology:
Expanding the Research Base—*Peter S.
Jensen, Benedetto Vitiello, Henrietta
Leonard, and Thomas P. Laughren*

Federal Medications Development Programs: A Novel Approach to Providing Needed Pharmacotherapies

- 9** Introduction—*Frederick K. Goodwin*
- 15** Alzheimer's Disease Drug Development
and Testing at the National Institute on
Aging—*Neil S. Buckholz*
- 19** The National Institute of Mental Health—
Psychotherapeutic Medications
Development Program (PMDP): Status
1993—*Henry J. Haigler*

Psychotropic Drug Labeling: Regulatory, Pharmaceutical Industry, and Clinical Issues and Perspectives

- 23** A Pharmaceutical Industry Perspective on
Drug Labeling—*Donald S. Robinson*

NCDEU Update

- 27** Treatment of Bipolar Disorder: How Far
Have We Come?—*Heather Stone Hopkins
and Alan J. Gelenberg*

5HT_{1A} Receptors and Pharmacotherapy

- 39** Is Serotonin Receptor Down-Regulation
Linked to the Mechanism of Action of
Antidepressant Drugs?—*Stephen Stahl*

Dysthymia and Chronic Depressive States: Diagnostic and Pharmacotherapeutic Considerations

- 45** Overview of the Diagnosis, Prevalence,
and Comorbidity of Dysthymia—*Harry E.
Gwirtsman*
- 53** Psychopharmacological Treatment
Response of Patients with a *DSM-III*
Diagnosis of Dysthymic Disorder—*David
Bakish, Arun Ravindran, Cynthia
Hooper, and Yvon Lapierre*

Commentary

- 61** Screening and Evaluating Alternative and
Innovative Psychiatric Treatments: A
Contextual Framework—*L. Eugene
Arnold*

NCDEU Abstracts—1993 Annual Meeting

- 71** 1993 NCDEU Free Communications
(in alphabetical order by first author)
- 85** 1993 NCDEU Poster Sessions
(in alphabetical order by first author)

Vol. 30, No. 2—1994

**Posters and Free Communications -
1993 NCDEU Meeting****Depression**

- 145** Metabolic and Physiologic Consequences of Nortriptyline Treatment in the Elderly—*Bruce G. Pollock, James M. Perel, Cynthia F. Paradis, Amy L. Fasiczka, and Charles F. Reynolds III*
- 151** Are Selective Serotonin Reuptake Inhibitors Well Tolerated in Somatizing Depressives?—*Robert D. Linden, Charles S. Wilcox, Jon F. Heiser, Elaine Cavanaugh, and Peter G. Wisselink*
- 157** The Antidepressant Response to Tricyclics in Major Depressives Is Accelerated With Adjunctive Use of Methylphenidate—*Harry E. Gwirtsman, Martin P. Szuba, Lili Toren, and Michael Feist*
- 165** Long-Term Treatment of Depression With Nefazodone—*Susan F. Anton, Donald S. Robinson, Douglas L. Roberts, Terry T. Kensler, Patricia A. English, and Donald G. Archibald*

Anxiety and Related Disorders

- 171** Dose-Response Characterization of the Antipanic Effects of Imipramine—*Matig R. Mavissakalian and James M. Perel*
- 175** Discriminating Placebo and Drug in Generalized Anxiety Disorder (GAD) Trials: Single vs. Multiple Clinical Raters—*Vincent Glaudin, Ward T. Smith, James M. Ferguson, Eugene A. DuBoff, Murray H. Rosenthal, and Denis Mee-Lee*

- 179** A Comparison of Delusional and Nondelusional Body Dysmorphic Disorder in 100 Cases—*Katharine A. Phillips, Susan L. McElroy, Paul E. Keck, Jr., James I. Hudson, and Harrison G. Pope, Jr.*

Schizophrenia

- 187** Early Course of New-Onset Tardive Dyskinesia in Older Patients—*Jonathan P. Lacro, Patricia L. Gilbert, Jane S. Paulsen, Robert Fell, Anne Bailey, Charles Juels, Michael Caligiuri, Lou Ann McAdams, M. Jackuelyn Harris, and Dilip V. Jeste*
- 193** Pharmacokinetics of Risperidone in Chronic Schizophrenic Patients—*Richard L. Borison, Bruce Diamond, Ananda Pathiraja, and Richard C. Meibach*
- 199** Scales for the Assessment of Neuroleptic Response in Schizophrenic Children: Specific Measures Derived From the CPRS—*Elizabeth Kay Spencer, Murray Alpert, and Enrique R. Pouget*

Childhood-Onset Disorders

- 203** Naltrexone Plasma Levels, Clinical Response and Effect on Weight in Autistic Children—*Nilda M. Gonzalez, Magda Campbell, Arthur M. Small, Judith Shay, Lisa D. Bluhm, Phillip B. Adams, and Rodger L. Foltz*
- 209** Placebo Response in Aggressive Children With Conduct Disorder—*Laura E. Sanchez, Jorge L. Armenteros, Arthur M. Small, Magda Campbell, and Phillip B. Adams*

- 215** The Overt Aggression Scale in a Study of Lithium in Aggressive Conduct Disorder—*Richard P. Malone, James Luebbert, Maria Pena-Ariet, Krista Biesecker, and Mary Anne Delaney*
- 219** Effects of Intravenous Dextroamphetamine on Brain Metabolism in Adults With Attention-Deficit Hyperactivity Disorder (ADHD). Preliminary Findings—*Monique Ernst, Alan J. Zametkin, John A. Matochik, Laura Liebenauer, Glinda A. Fitzgerald, and Robert M. Cohen*

Statistical Analysis

- 227** The Resampling Method of Statistical Analysis—*Simcha Pollack, Peter Bruce, Michael Borenstein, and Jeffrey Lieberman*
- 235** A Note on the Use of Confidence Intervals in Psychiatric Research—*Michael Borenstein*

Additional Topics

- 239** Clinical Sequelae of Overt Noncompliance With Psychotropic Agents—*Robert A. Littrell, Arch G. Mainous III, Fred Karem, Jr., W. Russell Coyle, and Chad M. Reynolds*
- 245** Self-Injurious Behavior and Serotonin in Prader-Willi Syndrome—*Jessica A. Hellings and Julia K. Warnock*

Commentary

- 251** Inhibition of Hepatic P-450 Isoenzymes by Serotonin Selective Reuptake Inhibitors: *In Vitro* and *In Vivo* Findings and Their Implications for Patient Care—*Sheldon H. Preskorn and Ryan D. Magnus*

Vol. 30, No. 3—1994

New Directions for ECT Research

- 265** Introduction—*Frederick K. Goodwin*
- 269** Indications for the Use of ECT—*Max Fink*
- 276** Group Discussion
- 281** Central Issues Regarding The Mechanisms of Action of Electroconvulsive Therapy: Directions for Future Research—*Harold A. Sackeim*
- 309** The Mode of Action of ECT—*Max Fink*
- 313** Treatment Optimization With ECT—*Richard D. Weiner*
- 321** Animal Studies of Electroconvulsive Therapy: Foundations for Future Research—*Laura J. Fochtmann*
- 445** Elucidation of Biochemical Basis of the Antidepressant Action of Electroconvulsive Therapy by Human Studies—*J. John Mann and Shitij Kapur*
- 455** ECT Methodologic Issues—*William Z. Potter*
- 461** Neuropsychology and ECT: Past and Future Research Trends—*Avraham Caley*
- 471** Patient Attitudes Toward Electroconvulsive Therapy—*Helen M. Pettinati, Traci A. Tamburello, Charles R. Ruetsch, and Frances N. Kaplan*
- 477** The Role of Structural Brain Imaging in ECT—*C. Edward Coffey*
- 485** The Thyroid and Electroconvulsive Treatment—*Russell T. Joffe and Stephen T.H. Sokolov*
- 489** Effects of Electroconvulsive Therapy on the CRH-ACTH-Cortisol System in Melancholic Depression: Preliminary Findings—*Mitchel A. Kling, Thomas D. Geraciotti, Julio Licinio, David Michelson, Edward H. Oldfield, and Philip W. Gold*
- 495** Electroconvulsive Therapy and Parkinson's Disease: The Case for Further Study—*Charles H. Kellner, Mark D. Beale, John T. Pritchett, Hilary J. Bernstein, and Carol M. Burns*
- 501** Continuation Therapy Following ECT: Directions for Future Research—*Harold A. Sackeim*

Vol. 30, No. 4—1994

Psychotherapeutic Medications Development Program (PMDP) Workshop on NMDA Receptor Antagonists: Neurotoxicity Evaluation

- 523** Editor's Note—*Matthew V. Rudorfer*
- 525** Foreword: Psychotherapeutic Medications Development Program (PMDP) Workshop on NMDA Receptor Antagonists: Neurotoxicity Evaluation—*Henry J. Haigler*
- 527** Introduction—*Paul Leber*
- 533** Neurotoxicity of NMDA Receptor Antagonists: An Overview—*John W. Olney*
- 541** Confocal Microscopic Visualization of MK-801-Induced Cytoplasmic Vacuoles *in Vitro*—*Jennifer K. Freeman and Mark P. Goldberg*
- 549** Biochemical Analysis of Glial Fibrillary Acidic Protein as a Quantitative Approach to Neurotoxicity Assessment: Advantages, Disadvantages and Application to the Assessment of NMDA Receptor Antagonist-Induced Neurotoxicity—*James P. O'Callaghan*
- 555** Neuronal Injury Produced By NMDA Antagonists Can Be Detected Using Heat Shock Proteins and Can Be Blocked With Antipsychotics—*F.R. Sharp, M. Butman, K. Aardalen, J. Nickolenko, R. Nakki, S.M. Massa, R.A. Swanson, and S.M. Sagar*
- 561** Effects of NMDA Receptor Antagonists on the Developing Brain—*Martha Constantine-Paton*

- 567** Developmental Aspects of NMDA Receptor Agonists and Antagonists in the Central Nervous System—*Michael V. Johnston*
- 577** Pathological Effects of MK-801 in the Rat Posterior Cingulate/Retrosplenial Cortex—*Andrew S. Fix*
- 585** Assessing Structural Changes in the Brain To Evaluate Neurotoxicological Effects of NMDA Receptor Antagonists—*Roland N. Auer*
- 593** Introduction to Principles and Procedures in Behavioral Testing—*Deborah C. Rice*
- 601** The Impact of NMDA Receptor Antagonists on Learning and Memory Functions—*Deborah A. Cory-Slechta*
- 613** Acute Behavioral Toxicity of MK-801 and Phencyclidine: Effects on Rhesus Monkey Performance in an Operant Test Battery—*Merle G. Paule*

Abstracts from the National Institute of Mental Health (NIMH)-sponsored New Clinical Drug Evaluation Unit (NCDEU) Meeting

- 623** Introduction
- 625** Free Communications
- 645** Poster Sessions

1994 Cumulative Table of Contents

1994 Cumulative Author Index

1994 Cumulative Keyword Index